The Effect of the Drug Medi-Cal Organized Delivery System 1115 Demonstration Waiver on Substance Use Disorder Treatment Access: Evidence from California

Drug Alcohol Depend. 2023 May 1:246:109847. doi: 10.1016/j.drugalcdep.2023.109847. Epub 2023 Mar 23.

Abstract

Background: In August 2015, the California Department of Health Care Services created the Drug Medi-Cal Organized Delivery System 1115 demonstration waiver (DMC-ODS waiver) to improve service delivery to Medi-Cal-eligible individuals with a substance use disorder (SUD). We examine if implementing the DMC-ODS waiver across California counties improved patient access to SUD treatment services.

Methods: We use administrative data from 2016 to 2020 from a reporting system for all publicly-funded SUD treatment services delivered in California and employ difference-in-differences and event study empirical strategies exploiting the differential timing of DMC-ODS waiver adoption across counties.

Results: Event study analyses show that eleven or more months after the introduction of the DMC-ODS waiver, the number of unique patient admissions significantly increase by nearly 20%. Residential treatment admissions significantly increase by roughly 25% in all months post-waiver introduction.

Conclusions: This study provides valuable information for policymakers about implementing 1115 waivers, and the important public health implications. California's DMC-ODS waiver has demonstrated that 1115 waivers similar to it can likely increase access to SUD treatment.

Keywords: 1115 waiver; Residential treatment; Substance use disorder treatment; Substance use disorder treatment access.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • California
  • Humans
  • Medicaid*
  • Pharmaceutical Preparations
  • United States

Substances

  • Pharmaceutical Preparations